82 related articles for article (PubMed ID: 8511992)
1. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease.
Delmas PD; Gineyts E; Bertholin A; Garnero P; Marchand F
J Bone Miner Res; 1993 May; 8(5):643-8. PubMed ID: 8511992
[TBL] [Abstract][Full Text] [Related]
2. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
[TBL] [Abstract][Full Text] [Related]
3. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
4. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ
J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
[TBL] [Abstract][Full Text] [Related]
5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
6. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
7. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases.
Arbault P; Grimaux M; Pradet V; Preaudat C; Seguin P; Delmas PD
Bone; 1995 Apr; 16(4):461-7. PubMed ID: 7605707
[TBL] [Abstract][Full Text] [Related]
8. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.
Seibel MJ; Woitge H; Scheidt-Nave C; Leidig-Bruckner G; Duncan A; Nicol P; Ziegler R; Robins SP
J Bone Miner Res; 1994 Sep; 9(9):1433-40. PubMed ID: 7817828
[TBL] [Abstract][Full Text] [Related]
9. [Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods].
Meddah B; Brazier M; Kamel S; Maamer M; Samson L; Desmet G; Sebert JL
Ann Biol Clin (Paris); 1996; 54(10-11):353-8. PubMed ID: 9092303
[TBL] [Abstract][Full Text] [Related]
10. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease.
Naylor KE; Jackson B; Eastell R
J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326
[TBL] [Abstract][Full Text] [Related]
11. Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects.
Ohishi T; Takahashi M; Kawana K; Aoshima H; Hoshino H; Horiuchi K; Kushida K; Inoue T
Clin Invest Med; 1993 Oct; 16(5):319-25. PubMed ID: 8261685
[TBL] [Abstract][Full Text] [Related]
12. Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks.
Schlemmer A; Hassager C; Pedersen BJ; Christiansen C
J Bone Miner Res; 1994 Dec; 9(12):1883-8. PubMed ID: 7872053
[TBL] [Abstract][Full Text] [Related]
13. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
[TBL] [Abstract][Full Text] [Related]
14. [Effect of clodronate in patients with multiple myeloma. Evaluation of specific markers of bone resorption].
Slabý J; Spicka I; Hulejová H; Spacek P; Cieslar P; Klener P
Cas Lek Cesk; 1997 Jan; 136(2):57-60. PubMed ID: 9147856
[TBL] [Abstract][Full Text] [Related]
15. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B
Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immuno- and HPLC-assays for the measurement of urinary collagen cross-links.
Calabresi E; Lasagni L; Franceschelli F; de Leonardis V; Becorpi A; Serio M; Brandi ML
J Endocrinol Invest; 1994 Sep; 17(8):625-9. PubMed ID: 7868800
[TBL] [Abstract][Full Text] [Related]
17. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay.
Garnero P; Grimaux M; Demiaux B; Preaudat C; Seguin P; Delmas PD
J Bone Miner Res; 1992 Dec; 7(12):1389-98. PubMed ID: 1481725
[TBL] [Abstract][Full Text] [Related]
18. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
[TBL] [Abstract][Full Text] [Related]
19. Immunoassay for urinary pyridinoline: the new marker of bone resorption.
Seyedin SM; Kung VT; Daniloff YN; Hesley RP; Gomez B; Nielsen LA; Rosen HN; Zuk RF
J Bone Miner Res; 1993 May; 8(5):635-41. PubMed ID: 8511991
[TBL] [Abstract][Full Text] [Related]
20. The renal clearance of free and conjugated pyridinium cross-links of collagen.
Colwell A; Eastell R
J Bone Miner Res; 1996 Dec; 11(12):1976-80. PubMed ID: 8970901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
